View On Demand

Program Cells Like You Program A Computer

About the Event, a synthetic biology company that was spun out of Cambridge University in 2016, has achieved a breakthrough in cell therapy. Their Opti-ox precision platform has the ability to create any human cell type and to manufacture it at scale with precision and consistency.

Register now to join this webinar with:

  • Mark Kotter, MD, PhD, Founder and CEO,
    Mark is a stem cell biologist and neurosurgeon at the University of Cambridge, the founder of and co-founder of the cultured meat start-up Meatable.
  • Alan S. Roemer, MBA, MPH, Board Member,
    Alan is an entrepreneurial life sciences executive and board member who has launched three multi-billion dollar biotechnology companies, raised over $1.75 billion in private and public capital, consummated five IPOs, and executed numerous life sciences technology transactions. 
  • Marie-Claire Cordonier Segger, PhD (Santa), DPhil (Oxon), MEM (Yale), LLB&BCL (McGill), BA Hons (Carl/UVic), FRSC, FRSA, WIJA, Chair of Ethics and Sustainability Board and Advisor to the Board,
    Marie-Claire is Visiting Chair of Sustainable Development Law and Policy at the University of Cambridge, and also serves as Senior Director of the global Centre for International Sustainable Development Law (CISDL). Having assisted in drafting the Paris Agreement, she has published over 24 books and 160 papers and edited five law journals. She has advised the United Nations, several countries, and companies to advance the UN Sustainable Development Goals.

Sign Up Today


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.